Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery

被引:27
|
作者
Yoh, Tomoaki [1 ]
Hatano, Etsuro [1 ]
Nishio, Takahiro [1 ]
Seo, Satoru [1 ]
Taura, Kojiro [1 ]
Yasuchika, Kentaro [1 ]
Okajima, Hideaki [1 ]
Kaido, Toshimi [1 ]
Uemoto, Shinji [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Surg, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan
关键词
BILIARY-TRACT CANCER; RESECTION; CHEMOTHERAPY; GEMCITABINE; RECURRENCE; SURVIVAL; METAANALYSIS; MANAGEMENT; CISPLATIN; TRIALS;
D O I
10.1007/s00268-016-3583-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The prognosis of intrahepatic cholangiocarcinoma (ICC) remains poor despite improvements in treatment and post-operative clinical management. We review our experiences and evaluate our current surgical approaches by comparing patients from two consecutive treatment periods. Methods One hundred forty-four patients who underwent hepatectomy for ICC between 1993 and 2014 were divided into groups that received treatment before (n = 65, first period) and after 2006 (n = 79, second period), when new treatment options such as adjuvant chemotherapy and multimodal therapy for recurrence were introduced. Clinicopathological characteristics and survival outcomes were compared between the groups. Results First-period patients exhibited more advanced tumor characteristics, including larger tumors, higher serum carbohydrate antigen 19-9 levels, and vascular invasion. Median overall survival (OS) durations of the first-and second-period groups were 21.4 and 57.7 months, respectively (p < 0.001); corresponding median disease-free survival (DFS) durations were 12.2 and 16.6 months, respectively (p = 0.027). Multivariate analysis found an independent association of the treatment time period with OS and DFS. Notably, second-period patients with N1 disease achieved a longer OS and DFS (median OS time: 12.4 and 26.0 months, p = 0.0018, and median DFS: 4.7 and 10.7 months p = 0.019, respectively). Among recurrent patients (first, n = 50 and second, n = 44), second-period patients had a significantly longer survival after recurrence (8.0 vs. 22.3 months, p < 0.001). Conclusion ICC patients, particularly those with N1 disease, achieved significant survival improvements that were partly attributable to patient selection, adjuvant chemotherapy, and multimodal treatment after recurrence.
引用
收藏
页码:2229 / 2236
页数:8
相关论文
共 50 条
  • [21] Surgery and chemotherapy for intrahepatic cholangiocarcinoma
    Morise, Zenichi
    Sugioka, Atsushi
    Tokoro, Takamasa
    Tanahashi, Yoshinao
    Okabe, Yasuhiro
    Kagawa, Tadashi
    Takeura, Chinatsu
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (02) : 58 - 64
  • [22] Surgical outcomes of intrahepatic cholangiocarcinoma
    Masakazu Yamamoto
    Shun-ichi Ariizumi
    Surgery Today, 2011, 41 : 896 - 902
  • [23] Radical surgery in intrahepatic cholangiocarcinoma
    Peycru, T.
    Hardwigsen, J.
    Gregoire, E.
    Barbier, L.
    Richa, H.
    Campan, P.
    Le Treut, Y-P.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 (03): : 187 - 193
  • [24] Surgical outcomes for intrahepatic cholangiocarcinoma
    Iso, Yukihiro
    Aoki, Taku
    Shiraki, Takayuki
    Park, Kyung Hwa
    Tani, Keigo
    Suzuki, Takashi
    Shimizu, Takayuki
    Matsumoto, Takatsugu
    Mori, Shozo
    Kato, Masato
    Kubota, Keiichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 173 - 173
  • [25] Surgical Outcomes of Intrahepatic Cholangiocarcinoma
    Yamamoto, Masakazu
    Ariizumi, Shun-ichi
    SURGERY TODAY, 2011, 41 (07) : 896 - 902
  • [26] Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma
    Tamandl, D.
    Kaczirek, K.
    Gruenberger, B.
    Koelblinger, C.
    Maresch, J.
    Jakesz, R.
    Gruenberger, T.
    BRITISH JOURNAL OF SURGERY, 2009, 96 (08) : 919 - 925
  • [27] Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection
    Song, Peipei
    Midorikawa, Yutaka
    Nakayama, Hisashi
    Higaki, Tokio
    Moriguchi, Masamichi
    Aramaki, Osamu
    Yamazaki, Shintaro
    Aoki, Masaru
    Teramoto, Kenichi
    Takayama, Tadatoshi
    CANCER MEDICINE, 2019, 8 (13): : 5862 - 5871
  • [28] Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection
    Rahnemai-Azar, Amir A.
    Pandey, Pallavi
    Kamel, Ihab
    Pawlik, Timothy M.
    HEPATIC ONCOLOGY, 2016, 3 (04) : 223 - 239
  • [29] Association of Distance Traveled with Cancer Outcomes in Patients with Intrahepatic Cholangiocarcinoma
    Tran, Thuy
    Malhotra, Gautam K.
    Raoof, Mustafa
    Singh, Gagandeep
    Fong, Yuman
    Melstrom, Laleh
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 441 - 441
  • [30] Textbook oncologic outcomes among patients undergoing laparoscopic, robotic and open surgery for intrahepatic and perihilar cholangiocarcinoma
    Munir, Muhammad M.
    Dillhoff, Mary
    Tsai, Susan
    Pawlik, Timothy M.
    HPB, 2024, 26 (08) : 1051 - 1061